Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′,5′ guanosine monophosphate (cGMP) level in podocytes-Reference-Cited by-同舟云学术

Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′,5′ guanosine monophosphate (cGMP) level in podocytes

Published:2012-11-29 Issue:7 Volume:28 Page:1751-1761
ISSN:1460-2385
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:

Author:

Fang Lilla,Radovits Tamás,Szabó Gábor,Mózes Miklós M.,Rosivall László,Kökény Gábor

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/28/7/1751/17173046/gfs391.pdf

Reference50 articles.

1. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions;Suzuki;J Am Soc Nephrol,1999

2. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy;Wolf;Diabetes,2005

3. Structural–functional correlations of diabetic nephropathy;Mauer;Kidney Int,1994

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase;European Journal of Medicinal Chemistry;2024-11

2. Possible retinotoxicity of long-term vardenafil treatment;Experimental Eye Research;2024-06

3. A Review of Antidiabetic Medicinal Plants as a Novel Source of Phosphodiesterase Inhibitors: Future Perspective of New Challenges Against Diabetes Mellitus;Medicinal Chemistry;2024-06

4. Unraveling the Nephroprotective Potential of Papaverine against Cisplatin Toxicity through Mitigating Oxidative Stress and Inflammation: Insights from In Silico, In Vitro, and In Vivo Investigations;Molecules;2024-04-23

5. Network pharmacology combined with Mendelian randomization analysis to identify the key targets of renin-angiotensin-aldosterone system inhibitors in the treatment of diabetic nephropathy;Frontiers in Endocrinology;2024-01-25